Results 1 to 10 of about 5,545,002 (288)

From Concept to Regulatory Drug Approval: Lessons for Theranostics. [PDF]

open access: yesJ Nucl Med, 2022
Radiopharmaceutical therapy is an emerging treatment modality that has demonstrated increasing importance as a significant component in the treatment of cancer.
Perera M, Morris MJ.
europepmc   +2 more sources

FDA Drug Approval and the Ethics of Desperation. [PDF]

open access: yesJAMA Intern Med, 2021
In justifying the accelerated approval of aducanumab (Aduhelm; Biogen), US Food and Drug Administration (FDA) officials emphasized that many patients with Alzheimer disease and their families “made it clear that they are willing to accept the trade-off ...
Largent EA, Peterson A, Lynch HF.
europepmc   +2 more sources

Conditional Drug Approval as a Path to Market for Oncology Drugs in Canada: Challenges and Recommendations for Assessing Eligibility and Regulatory Responsiveness. [PDF]

open access: yesFront Med (Lausanne), 2021
International drug regulators use conditional drug approval mechanisms to facilitate faster patient access to drugs based on a lower evidentiary standard typically required of drug approvals. Faster and earlier access is justified by limiting eligibility
McPhail M, Weiss E, Bubela T.
europepmc   +2 more sources

An open science pathway for drug marketing authorization-Registered drug approval. [PDF]

open access: yesPLoS Medicine, 2021
Florian Naudet and co-authors propose a pathway involving registered criteria for evaluation and approval of new drugs.
Florian Naudet   +4 more
doaj   +3 more sources

Evolving Landscape of New Drug Approval in Japan and Lags from International Birth Dates: Retrospective Regulatory Analysis. [PDF]

open access: yesClin Pharmacol Ther, 2021
The Pharmaceuticals and Medical Devices Agency (PMDA) has approved hundreds of new drugs in recent years. We retrospectively analyzed the new drugs approved in Japan from 2008 to 2019, and identify the first‐in‐world approvals and clarify the current ...
Tanaka M   +10 more
europepmc   +2 more sources

Predictors of orphan drug approval [PDF]

open access: yesOrphanet Journal of Rare Diseases, 2010
Results More orphan drugs were developed in the US during the first ten years of the US Orphan Drug Act (1983-1992, N=73) and during the first ten years of the EU Regulation on Orphan Medicinal products (2000-2009, N=112) than in the EU (2000-2009, N=59). Orphan drug approval was strongly associated with previous experiences of the sponsor in obtaining
Heemstra Harald
doaj   +3 more sources

From Drug Discovery to Drug Approval: A Comprehensive Review of the Pharmacogenomics Status Quo with a Special Focus on Egypt [PDF]

open access: yesPharmaceuticals
Pharmacogenomics (PGx) is the hope for the full optimization of drug therapy while minimizing the accompanying adverse drug events that cost billions of dollars annually.
Fadya M. Elgarhy   +7 more
doaj   +2 more sources

Getting the Right Evidence After Drug Approval [PDF]

open access: yesFrontiers in Pharmacology, 2020
To generate comparative evidence in a timely fashion for drugs without restricting or delaying access, value-based pricing and reimbursement could be conditioned on a prospective, post-approval evidence generation plan.
Rick A. Vreman   +3 more
doaj   +2 more sources

Adapting drug approval pathways for bacteriophage-based therapeutics

open access: yesFrontiers in Microbiology, 2016
The global rise of multi-drug resistant bacteria has resulted in the notion that an antibiotic apocalypse is fast approaching. This has led to a number of well publicized calls for global funding initiatives to develop new antibacterial agents. The long
Callum Cooper   +3 more
doaj   +2 more sources

Approval success rates of drug candidates based on target, action, modality, application, and their combinations

open access: yesClinical and Translational Science, 2021
The current success rate of a drug candidate, from the beginning of the clinical trial to receiving marketing approval, is about 10%–20%, and it has not changed during the past few decades. Therefore, pharmaceutical companies are under pressure to select
Shingo Yamaguchi   +2 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy